AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518 IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Lymphoblastic Leukaemia [all]
  • Age: Between 1 - 21 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients must have B-Acute Lymphoblastic Leukemia (B-ALL) 2. Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy

You may not be eligible for this study if the following are true:

  • 1. Patients with any prior history of SOS/VOD irrespective of severity 2. Patients with isolated CNS, testicular, or other extramedullary site of relapse. 3. Patients who have been previously treated with InO.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.